Results 51 to 60 of about 1,785 (194)

Omadacycline therapy for Mycobacterium abscessus species infections

Internal Medicine Journal, Volume 53, Issue 12, Page 2257-2263, December 2023., 2023
Abstract Background Antimicrobial resistance and therapy‐related adverse effects make Mycobacterium abscessus treatment challenging. Omadacycline is a novel, bioavailable aminomethylcycline with favourable in vitro activity against M. abscessus. Aims To describe a case report and review the published literature describing outcomes for M.
Paul R. Ingram, Eva E. Jones, Bethwyn Allen, Ronan J. Murray, Terillee J. Keehner, Timothy J. Whitmore   +5 more
wiley   +1 more source

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics

Antimicrobial Agents and Chemotherapy, 2023
Omadacycline is approved in the United States for the treatment of patients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections. Analyses were undertaken to evaluate pharmacokinetic differences among subjects or patients stratified by comorbidities.
M. Trang, E. A. Lakota, M. C. Safir, S. M. Bhavnani, L. Friedrich, J. N. Steenbergen, P. C. McGovern, E. Tzanis, C. M. Rubino   +8 more
openaire   +2 more sources

Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.

, 2023
Click on the Resource Link to access the article (may not be free).Omadacycline is an amino-methylcycline antibiotic that is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin ...
Yim, Erica, Berman, Gail, Mu, Fan, Yang, Danni, Gunter, Kyle, Lodise, Thomas P, Gao, Emily, Sandor, Steve   +7 more
core   +1 more source

DataSheet1_Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects.docx

, 2022
Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved
Jingjing Wang (140791), Jun Deng (239794), Zhiwei Huang (116200), Harald Reinhart (12438216), Jufang Wu (8744985), Yuancheng Chen (276967), Yan Guo (83742), Jing Liu (38537), Yusong Zhu (1983280), Xiaojie Wu (404013), Jicheng Yu (1527280), Lichuan Liu (438088), Jing Zhang (23775), Guoying Cao (8214485), Haijing Yang (12438213)   +14 more
core   +1 more source

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline [PDF]

Clinical Infectious Diseases, 2019
AbstractOral and intravenous (IV) omadacycline formulations are approved in the United States for treating acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. Oral omadacycline bioavailability is 34.5%; similar exposures are obtained following 300 mg oral and 100 mg IV doses.
Rodvold, Keith A, Pai, Manjunath P
openaire   +2 more sources

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.

, 2021
BACKGROUND AND OBJECTIVE: Omadacycline is an aminomethylcycline antibiotic approved in the USA as once-daily intravenous/oral monotherapy for adults with community-acquired bacterial pneumonia (CABP).
LaPensee, Kenneth, Lodise, Thomas P, Mistry, Rohit, Young, Kate   +3 more
core   +1 more source

Omadacycline: a novel aminomethylcycline.

Infection and drug resistance, 2019
Tetracyclines have come a long way since they became available almost seven decades ago, with numerous enhancements allowing new agents to overcome bacterial mechanisms of resistance. However, these enhancements come with toxicities and pharmacokinetic disadvantages such as the gastrointestinal side-effects and poor oral bioavailability seen with the ...
Burgos,Rodrigo M, Rodvold,Keith A
openaire   +5 more sources

Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective

Antibiotics, 2021
Introduction: Approximately 3% of hospitalized patients with community-acquired bacterial pneumonia (CABP) develop healthcare-associated Clostridioides difficile infection (HCA-CDI). The validated Davis risk score (DRS) indicates that patients with a DRS
Thomas Lodise, Mauricio Rodriguez, Surya Chitra, Kelly Wright, Nimish Patel   +4 more
doaj   +1 more source

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in Microbiology, 2020
Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee, Yi-Tzu Lee, Hsing-Yu Chen, Ya-Sung Yang, Yu-Ching Chou, Tein-Yao Chang, Wei-Jane Hsu, I-Chieh Lin, ACTION Study Group, Jun-Ren Sun   +9 more
doaj   +1 more source

Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates [PDF]

, 2018
Omadacycline was tested against 125 isolates recovered from infected cat and dog bites in humans. Its activity was similar to that of other compounds in the tetracycline class, and it was active against strains exhibiting tetracycline resistance. Against
Ellie J. C. Goldstein, C. Vreni Merriam, Citron, Diane M, Merriam, C Vreni, Eliza Leoncio, Tyrrell, Kerin L, Diane M. Citron, Kerin L. Tyrrell, Goldstein, Ellie JC, Leoncio, Eliza   +9 more
core   +1 more source